Skip to main content
Clinical Trials/IRCT20150101020514N24
IRCT20150101020514N24
Recruiting
Phase 2

Evaluating the safety and effectiveness of injectable gel with the Perjunse brand, for correcting nasolabial folds, before and after single clinical trial

Pars Fardad Nano Technology Company0 sites30 target enrollmentTBD
ConditionsSkin aging.

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Skin aging.
Sponsor
Pars Fardad Nano Technology Company
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Pars Fardad Nano Technology Company

Eligibility Criteria

Inclusion Criteria

  • 18\-65 year old men and women
  • Moderate to severe nasolabial folds based on Allergan criteria
  • The opportunity to accompany the visit programs and study process.
  • Signing the informed consent form and agree to a 6\-month follow\-up

Exclusion Criteria

  • Previous hyaluronic acid (HA)\-based dermal filler treatment(s) injected within the last 12 months prior to enrollment.
  • Cosmetic facial procedures (chemical peel, laser, radio frequency, dermabrasion, ablative or non\-ablative procedures), Botox) in the lower 2/3 of the face, within 3 months prior to study entry
  • Planning to undergo any of these procedures at any time during the study
  • Any cosmetic facial procedures during last 3 months
  • Allergy to gram positive bacteria protein, gel ingredients
  • Auto immune or immune deficiency diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials